AGEs, RAGE, and Diabetic Retinopathy (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4867–74.
    Article PubMed Google Scholar
  2. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–56.
    Article PubMed CAS Google Scholar
  3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–16.
    Article PubMed CAS Google Scholar
  4. Mannervik B. Molecular enzymology of the glyoxalase system. Drug Metabol Drug Interact. 2008;23:13–27.
    Article PubMed CAS Google Scholar
  5. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287–91.
    Article PubMed CAS Google Scholar
  6. Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1alpha and MCP-1 levels in type 2 diabetic patients. Eur J Nutr. 2010;49:429–34.
    Article PubMed CAS Google Scholar
  7. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337–46.
    PubMed CAS Google Scholar
  8. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body’s AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci. 2005;1043:461–6.
    Article PubMed CAS Google Scholar
  9. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143–52.
    Article PubMed CAS Google Scholar
  10. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diab Metab Res Rev. 2001;17:436–43.
    Article CAS Google Scholar
  11. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987–97.
    PubMed CAS Google Scholar
  12. • Kalea AZ, Schmidt AM, Hudson BI. RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond) 2009, 116:621–637. This study has had an important impact because it reviewed the role of RAGE in the pathogenesis of vascular disease and contains all the seminal research in this field.
  13. Osawa M, Yamamoto Y, Munesue S, et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim Biophys Acta. 2007;1770:1468–74.
    PubMed CAS Google Scholar
  14. Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem. 2007;282:31317–31.
    Article PubMed CAS Google Scholar
  15. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901.
    Article PubMed CAS Google Scholar
  16. Hudson BI, Carter AM, Harja E, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22:1572–80.
    Article PubMed CAS Google Scholar
  17. Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–7.
    Article PubMed CAS Google Scholar
  18. Zong H, Madden A, Ward M, Mooney MH, Elliott CT, Stitt AW. Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem. 2010;285:23137–46.
    Article PubMed CAS Google Scholar
  19. Yan SF, Ramasamy R, Bucciarelli LG, et al. RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res. 2004;1:10–20.
    Article PubMed Google Scholar
  20. Hudson BI, Kalea AZ, Del Mar Arriero M, et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem. 2008;283:34457–68.
    Article PubMed CAS Google Scholar
  21. Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem. 2010;285:23233–40.
    Article PubMed CAS Google Scholar
  22. Takuma K, Fang F, Zhang W, et al. RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci USA. 2009;106:20021–6.
    PubMed CAS Google Scholar
  23. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;274:19919–24.
    Article PubMed CAS Google Scholar
  24. Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent upregulation of chemokine expression and release. J Biol Chem 2011
  25. Fosmark DS, Bragadottir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case-control study. Acta Ophthalmol Scand. 2007;85:618–22.
    Article PubMed CAS Google Scholar
  26. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764–9.
    Article PubMed CAS Google Scholar
  27. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun. 2000;3:380–8.
    Article PubMed CAS Google Scholar
  28. Stitt AW, Curtis TM. Advanced glycation and retinal pathology during diabetes. Pharmacol Rep. 2005;57(Suppl):156–68.
    PubMed Google Scholar
  29. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2916–24.
    Article PubMed Google Scholar
  30. •• Zong H, Ward M, Madden A, et al.. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia 2010, 53:2656–2666. This paper demonstrated that RAGE interaction with its ligands plays an important role in retinal glial dysfunction during diabetic retinopathy. RAGE and its ligand S100B were induced by hyperglycemia in Müller glia, in vitro and in vivo. The early induction of S100B/RAGE expression by hyperglycemia in Muller glia results in the elevated levels of proinflammatory cytokines including VEGF and MCP-1, which are key mediators for diabetic retinopathy. This response can be attenuated by sRAGE or RAGE small interfering RNA, implicating the critical role of RAGE in the initiation of diabetic retinopathy.
  31. • Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249–255. This paper is important because it evaluated the induction of RAGE and its ligands, S100A8, S100A12, and HMGB1, in human aortic endothelial cells and indicated modulation by ROS. This suggests that ROS cannot only be induced as the end point of RAGE activation, but also act as a positive feedback of RAGE-mediated proinflammatory signaling.
  32. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699–712.
    Article PubMed CAS Google Scholar
  33. Hirata C, Nakano K, Nakamura N, et al. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. Biochem Biophys Res Commun. 1997;236:712–15.
    Article PubMed CAS Google Scholar
  34. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes. 1998;47:815–20.
    Article PubMed CAS Google Scholar
  35. Curtis TM, Hamilton R, Yong PH, et al. Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia. 2011;54:690–8.
    Article PubMed CAS Google Scholar
  36. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33:637–68.
    Article PubMed CAS Google Scholar
  37. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.
    PubMed CAS Google Scholar
  38. Schalkwijk CG, Ligtvoet N, Twaalfhoven H, et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes. 1999;48:2446–53.
    Article PubMed CAS Google Scholar
  39. Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci. 2003;44:4457–64.
    Article PubMed Google Scholar
  40. Chen BH, Jiang DY, Tang LS. Advanced glycation end-products induce apoptosis involving the signaling pathways of oxidative stress in bovine retinal pericytes. Life Sci. 2006;79:1040–8.
    Article PubMed CAS Google Scholar
  41. Foulds WS. The choroidal circulation and retinal metabolism–an overview. Eye (Lond). 1990;4(Pt 2):243–8.
    Google Scholar
  42. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest. 1998;101:1219–24.
    Article PubMed CAS Google Scholar
  43. Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006;281:20213–20.
    Article PubMed CAS Google Scholar
  44. Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability. Biochimie. 2010;92:1040–51.
    Article PubMed CAS Google Scholar
  45. Nitti M, Furfaro AL, Traverso N, et al. PKC delta and NADPH oxidase in AGE-induced neuronal death. Neurosci Lett. 2007;416:261–5.
    Article PubMed CAS Google Scholar
  46. Wang Y, Vom Hagen F, Pfister F, et al. Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann NY Acad Sci. 2008;1126:42–5.
    Article PubMed CAS Google Scholar
  47. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88:11555–8.
    Article PubMed CAS Google Scholar
  48. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res. 2007;2007:51837.
    PubMed Google Scholar
  49. Yatoh S, Mizutani M, Yokoo T, et al. Antioxidants and an inhibitor of advanced glycation ameliorate death of retinal microvascular cells in diabetic retinopathy. Diabetes Metab Res Rev. 2006;22:38–45.
    Article PubMed CAS Google Scholar
  50. Bhatwadekar A, Glenn JV, Figarola JL, et al. A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. Br J Ophthalmol. 2008;92:545–7.
    Article PubMed CAS Google Scholar
  51. Kaji Y, Usui T, Ishida S, et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest Ophthalmol Vis Sci. 2007;48:858–65.
    Article PubMed Google Scholar
  52. Chen Y, Akirav EM, Chen W, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008;181:4272–8.
    PubMed CAS Google Scholar
  53. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease. Alzheimer Dis Assoc Disord 2010
  54. Yamamoto K, Kitayama W, Denda A, Sasahira T, Kuniyasu H, Kirita T. Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac. Pathobiology. 2006;73:317–24.
    Article PubMed CAS Google Scholar
  55. Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2008;40:10–5.
    Article PubMed CAS Google Scholar
  56. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes. 2004;53:2662–8.
    Article PubMed CAS Google Scholar
  57. Yamagishi S, Takeuchi M. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs Exp Clin Res. 2004;30:169–75.
    PubMed CAS Google Scholar
  58. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev. 2010;6:304–12.
    Article PubMed CAS Google Scholar
  59. Abdallah W, Fawzi AA. Anti-VEGF therapy in proliferative diabetic retinopathy. Int Ophthalmol Clin. 2009;49:95–107.
    Article PubMed Google Scholar
  60. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726–33.
    Article PubMed Google Scholar
  61. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
    Article PubMed CAS Google Scholar
  62. Arevalo JF, Maia M, Flynn Jr HW, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213–16.
    Article PubMed CAS Google Scholar
  63. Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011.
  64. Kim OS, Kim J, Kim CS, Kim NH, Kim JS. KIOM-79 prevents methyglyoxal-induced retinal pericyte apoptosis in vitro and in vivo. J Ethnopharmacol. 2010;129:285–92.
    Article PubMed Google Scholar
  65. Wang Q, Pfister F, Dorn-Beineke A, et al. Low-dose erythropoietin inhibits oxidative stress and early vascular changes in the experimental diabetic retina. Diabetologia. 2010;53:1227–38.
    Article PubMed CAS Google Scholar
  66. Yamagishi S, Nakamura K, Matsui T, Takeuchi M. Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. Med Hypotheses. 2006;66:273–5.
    Article PubMed CAS Google Scholar
  67. Kowluru RA, Kanwar M, Chan PS, Zhang JP. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients. Arch Ophthalmol. 2008;126:1266–72.
    Article PubMed Google Scholar

Download references